Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis

Jennifer L. Snead, Thomas O'Hare, Lauren T. Adrian, Christopher A. Eide, Thoralf Lange, Brian Druker, Michael W. Deininger

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Pioneering work with the Bcr-Abl inhibitor, imatinib, demonstrated a requirement for constant Bcr-Abl inhibition to achieve maximal therapeutic benefit in treating chronic myeloid leukemia (CML), establishing a paradigm that has guided further drug development for this disease. Surprisingly, the second-generation Bcr-Abl inhibitor, dasatinib, was reported to be clinically effective with once-daily dosing, despite a short (3- to 5-hour) plasma half-life. Consistent with this observation, dasatinib treatment of progenitor cells from chronic-phase CML patients for 4 hours, followed by washout, or continuously for 72 hours both resulted in an induction of apoptosis and a reduction in the number of clonogenic cells. Such acute treatments with clinically achievable dasatinib concentrations also irreversibly committed Bcr-Abl+ CML cell lines to apoptotic cell death. Potent transient Bcr-Abl inhibition using the alternative inhibitor, nilotinib, also resulted in cell death. These findings demonstrate that in vitro assays designed to model in vivo pharmacokinetics can predict clinical efficacy. Furthermore, they challenge the widely held notion that continuous target inhibition is required for optimal efficacy of kinase inhibitors.

Original languageEnglish (US)
Pages (from-to)3459-3463
Number of pages5
JournalBlood
Volume114
Issue number16
DOIs
StatePublished - 2009

Fingerprint

Cell death
Apoptosis
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Cell Death
Leukemia, Myeloid, Chronic Phase
Pharmacokinetics
Myeloid Cells
Half-Life
Assays
Phosphotransferases
Stem Cells
Therapeutics
Cell Count
Cells
Plasmas
Cell Line
Pharmaceutical Preparations
Dasatinib
Imatinib Mesylate
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Snead, J. L., O'Hare, T., Adrian, L. T., Eide, C. A., Lange, T., Druker, B., & Deininger, M. W. (2009). Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. Blood, 114(16), 3459-3463. https://doi.org/10.1182/blood-2007-10-113969

Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. / Snead, Jennifer L.; O'Hare, Thomas; Adrian, Lauren T.; Eide, Christopher A.; Lange, Thoralf; Druker, Brian; Deininger, Michael W.

In: Blood, Vol. 114, No. 16, 2009, p. 3459-3463.

Research output: Contribution to journalArticle

Snead, JL, O'Hare, T, Adrian, LT, Eide, CA, Lange, T, Druker, B & Deininger, MW 2009, 'Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis', Blood, vol. 114, no. 16, pp. 3459-3463. https://doi.org/10.1182/blood-2007-10-113969
Snead, Jennifer L. ; O'Hare, Thomas ; Adrian, Lauren T. ; Eide, Christopher A. ; Lange, Thoralf ; Druker, Brian ; Deininger, Michael W. / Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis. In: Blood. 2009 ; Vol. 114, No. 16. pp. 3459-3463.
@article{387aa971bb5b44f2821ead9bf9d603d5,
title = "Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis",
abstract = "Pioneering work with the Bcr-Abl inhibitor, imatinib, demonstrated a requirement for constant Bcr-Abl inhibition to achieve maximal therapeutic benefit in treating chronic myeloid leukemia (CML), establishing a paradigm that has guided further drug development for this disease. Surprisingly, the second-generation Bcr-Abl inhibitor, dasatinib, was reported to be clinically effective with once-daily dosing, despite a short (3- to 5-hour) plasma half-life. Consistent with this observation, dasatinib treatment of progenitor cells from chronic-phase CML patients for 4 hours, followed by washout, or continuously for 72 hours both resulted in an induction of apoptosis and a reduction in the number of clonogenic cells. Such acute treatments with clinically achievable dasatinib concentrations also irreversibly committed Bcr-Abl+ CML cell lines to apoptotic cell death. Potent transient Bcr-Abl inhibition using the alternative inhibitor, nilotinib, also resulted in cell death. These findings demonstrate that in vitro assays designed to model in vivo pharmacokinetics can predict clinical efficacy. Furthermore, they challenge the widely held notion that continuous target inhibition is required for optimal efficacy of kinase inhibitors.",
author = "Snead, {Jennifer L.} and Thomas O'Hare and Adrian, {Lauren T.} and Eide, {Christopher A.} and Thoralf Lange and Brian Druker and Deininger, {Michael W.}",
year = "2009",
doi = "10.1182/blood-2007-10-113969",
language = "English (US)",
volume = "114",
pages = "3459--3463",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "16",

}

TY - JOUR

T1 - Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis

AU - Snead, Jennifer L.

AU - O'Hare, Thomas

AU - Adrian, Lauren T.

AU - Eide, Christopher A.

AU - Lange, Thoralf

AU - Druker, Brian

AU - Deininger, Michael W.

PY - 2009

Y1 - 2009

N2 - Pioneering work with the Bcr-Abl inhibitor, imatinib, demonstrated a requirement for constant Bcr-Abl inhibition to achieve maximal therapeutic benefit in treating chronic myeloid leukemia (CML), establishing a paradigm that has guided further drug development for this disease. Surprisingly, the second-generation Bcr-Abl inhibitor, dasatinib, was reported to be clinically effective with once-daily dosing, despite a short (3- to 5-hour) plasma half-life. Consistent with this observation, dasatinib treatment of progenitor cells from chronic-phase CML patients for 4 hours, followed by washout, or continuously for 72 hours both resulted in an induction of apoptosis and a reduction in the number of clonogenic cells. Such acute treatments with clinically achievable dasatinib concentrations also irreversibly committed Bcr-Abl+ CML cell lines to apoptotic cell death. Potent transient Bcr-Abl inhibition using the alternative inhibitor, nilotinib, also resulted in cell death. These findings demonstrate that in vitro assays designed to model in vivo pharmacokinetics can predict clinical efficacy. Furthermore, they challenge the widely held notion that continuous target inhibition is required for optimal efficacy of kinase inhibitors.

AB - Pioneering work with the Bcr-Abl inhibitor, imatinib, demonstrated a requirement for constant Bcr-Abl inhibition to achieve maximal therapeutic benefit in treating chronic myeloid leukemia (CML), establishing a paradigm that has guided further drug development for this disease. Surprisingly, the second-generation Bcr-Abl inhibitor, dasatinib, was reported to be clinically effective with once-daily dosing, despite a short (3- to 5-hour) plasma half-life. Consistent with this observation, dasatinib treatment of progenitor cells from chronic-phase CML patients for 4 hours, followed by washout, or continuously for 72 hours both resulted in an induction of apoptosis and a reduction in the number of clonogenic cells. Such acute treatments with clinically achievable dasatinib concentrations also irreversibly committed Bcr-Abl+ CML cell lines to apoptotic cell death. Potent transient Bcr-Abl inhibition using the alternative inhibitor, nilotinib, also resulted in cell death. These findings demonstrate that in vitro assays designed to model in vivo pharmacokinetics can predict clinical efficacy. Furthermore, they challenge the widely held notion that continuous target inhibition is required for optimal efficacy of kinase inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=70350727160&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350727160&partnerID=8YFLogxK

U2 - 10.1182/blood-2007-10-113969

DO - 10.1182/blood-2007-10-113969

M3 - Article

C2 - 19706883

AN - SCOPUS:70350727160

VL - 114

SP - 3459

EP - 3463

JO - Blood

JF - Blood

SN - 0006-4971

IS - 16

ER -